Martin Shkreli: 'Delusional' jailed 'pharma bro' denied early release from prison to find coronavirus cure
Disgraced former pharmaceutical executive claimed he could help find treatment for Covid-19
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A judge has rejected a request by disgraced pharmaceutical executive Martin Shkreli to be released from prison amid the coronavirus pandemic.
Shkreli, known as the "Parma Bro", is serving a seven-year sentence after being convicted in 2017 for lying to investors about the performance of two hedge funds he was running, as well as defrauding investors in a drug company.
His lawyers had argued that if released from a low-security prison in Allenwood, Pennsylvania, he would be about to research a treatment for the coronavirus, which has infected 1.4 million Americans and killed more than 88,000.
However the claim was dismissed by probation officials as being the kind of "delusional self-aggrandising behaviour" that had led to his conviction.
US district judge Kiyo Matsumoto released a nine-page ruling denying Shkreli's request to be freed, saying the 37-year-old had failed to demonstrate extraordinary and compelling factors that would require his release.
Benjamin Brafman, Shkreli's attorney, said the decision was "disappointing but not unexpected".
In a research proposal posted online, Shkreli said the pharmaceutical industry's response to the pandemic was "inadequate" and said researchers at every drug company "should be put to work until Covid-19 is no more".
He said his background "as a successful two-time biopharma entrepreneur, having purchased multiple companies, invented multiple new drug candidates" would make him a valuable asset.
However, the judge noted the concerns of probation officials that Shkreli's claim that he could develop a cure for coronavirus that "so far eluded the best medical and scientific minds in the world working around the clock" is "delusional self-aggrandising behaviour".
Shkreli first gained notoriety by buying the rights to a drug used to treat an infection that occurs in some Aids, malaria and cancer patients and raising the price from $13.50 to $750 per pill. He is also known for attacking critics on social media and offering a bounty to anyone who could give him one of Hillary Clinton's hairs.
A number of high profile prisoners have been released due to the coronavirus pandemic.
Hip-hop star Tekashi 6ix9ine, who was serving two years for gang-related activity, was released into home confinement, as was Paul Manafort, Donald Trump's former campaign manager who was serving seven and a half years for tax evasion and unregistered lobbying.
Former Hollywood producer Harvey Weinstein, jailed for 23 years for sex attacks, was reported in March to have contracted Covid-19, although his spokesman later said his client no longer had any symptoms.
The Associated Press contributed to this report
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments